Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | GEN1044 |
Synonyms | |
Therapy Description |
GEN1044 is a recombinant bispecific antibody that targets the human T-cell co-receptor CD3 and the oncofetal antigen 5T4, potentially leading to a cytotoxic T-cell response and inhibition of tumor cell cell proliferation (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
GEN1044 | GEN 1044|GEN-1044|DuoBody-CD3x5T4|Anti-CD3/Anti-5T4 Bispecific Antibody GEN1044 | CD3 Antibody 99 | GEN1044 is a recombinant bispecific antibody that targets the human T-cell co-receptor CD3 and the oncofetal antigen 5T4, potentially leading to a cytotoxic T-cell response and inhibition of tumor cell cell proliferation (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04424641 | Phase Ib/II | GEN1044 | A Study on the Safety of GEN1044 (DuoBody-CD3x5T4) in Subjects With Malignant Solid Tumors | Terminated | USA | ISR | ESP | DNK | 0 |